XML 32 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restructuring
12 Months Ended
Dec. 31, 2021
Restructuring and Related Activities [Abstract]  
Restructuring
8.
Restructuring

In February 2019, the Company implemented corporate changes to focus its resources on advancing its clinical-stage therapeutic candidates. In connection with the prioritization of these therapeutic candidates, the Company made changes to its management team and reduced headcount by approximately 30 percent.

During the year ended December 31, 2019 the Company recorded charges of $1,492, related to severance and other termination benefits. No restructuring charges were recorded during the years ended December 31, 2021 and 2020. During the year ended December 31, 2019 the Company paid $1,299 related to the restructuring and paid out the remaining $193 in 2020. There were no outstanding restructuring liabilities included in accrued expenses and other current liabilities as of December 31, 2021 and 2020.